ITGB2 and pulmonary fibrosis: We have also hypothesized that lovastatin may have inhibited LFA-1/ICAM interaction, impairing fibrocyte migration, which resulted in the observed decrease in circulating fibrocytes homing to the lung in our animal model of pulmonary fibrosis.